ganciclovir gel Zirgan
Selected indexed studies
- In-situ gel bases ocular delivery system of Ganciclovir, in-vivo and in-vitro investigation. (BMC Pharmacol Toxicol, 2025) [PMID:40361233]
- Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). (Drugs, 2011) [PMID:21443283]
- Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis. (Curr Eye Res, 2012) [PMID:22607463]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). (2011) pubmed
- Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis. (2012) pubmed
- In-situ gel bases ocular delivery system of Ganciclovir, in-vivo and in-vitro investigation. (2025) pubmed
- Cytomegalovirus Corneal Endotheliitis. (2026) pubmed
- Pharmacokinetics of ganciclovir eye drops: a comparative study of solutions prepared from ganciclovir for intravenous infusion and ganciclovir gel. (2024) pubmed
- Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. (2014) pubmed
- Efficacy and safety of ROH-101 (0.15% ganciclovir gel) for cytomegalovirus corneal endotheliitis: an open-label, uncontrolled, phase 3 study in Japan. (2025) pubmed
- Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. (1997) pubmed
- Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. (1994) pubmed
- Evaluation of topical ophthalmic ganciclovir gel for the treatment of dogs with experimentally induced ocular canine herpesvirus-1 infection. (2018) pubmed